Aprea Therapeutics Q2 net loss $3.3M; cash $27.7M; ATRN-119 data Q4 2023

Aprea Therapeutics, Inc.

2023-Q2 EPS reported -$2.18

Net loss $3.3M ($0.87/sh) vs $98.3M loss in Q2 2022, driven by absence of $76M IPR&D charge from Atrin deal.
Cash and equivalents $27.7M; management expects runway into Q4 2024.
R&D expenses down to $2.2M from $6.8M; G&A down to $1.7M from $15.6M YoY.
ATRN-119 Phase 1/2a enrollment ongoing; initial safety and PK data expected Q4 2023.
Gabriela Gruia, M.D., appointed to Board of Directors; over 25 years clinical and regulatory experience.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aprea Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $3.3 million, EPS $0.87 per basic share.

Period: the quarter ended June 30, 2023
Net income: $3.3 million
EPS: $0.87 per basic share
Result: reported results

Exact text from the filing

The Company reported a net loss of $3.3 million ($0.87 per basic share) on approximately 3.7 million weighted-average common shares outstanding for the quarter ended June 30, 2023

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-014403

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.